All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 9 November 2018, Gerald Wulf from University Medicine Göttingen, Göttingen, DE, and colleagues, published in Bone Marrow Transplantation an outcome analysis of allogeneic stem cell transplantation in relapsed or refractory (R/R) T-cell lymphoma patients.
Salvage chemotherapy is the standard of care for patients with peripheral T-cell lymphoma but leads to disease remission in approximately 30% of patients. Allogeneic stem cell transplantation (allo-SCT) or bone marrow transplantation (BMT) has been considered as a treatment option for R/R T-cell lymphoma patients but its efficacy and safety are still under consideration. The aim of this study was to analyze the outcomes of allo-SCT or -BMT in R/R T-cell lymphoma patients, following conditioning with fludarabine, busulfan, and cyclophosphamide (FBC). Outcome endpoints included overall survival (OS), disease-free survival, non-relapse mortality (NRM), and graft-versus-host disease (GvHD).
The results of this retrospective analysis revealed that allo-SCT or -BMT provided disease remission in approximately 38% of R/R T-cell lymphoma patients at a three-year follow-up. Moreover, OS was significantly lowered by prior high-dose chemotherapy with autologous SCT, increasing IPI, elevated LDH, ECOG > 1 and remission status before transplantation. According to the authors, allo-SCT is a curative treatment for a number of T-cell lymphoma patients and FBC an efficient conditioning regimen for advanced disease stages.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox